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Community acquired pneumonia (CAP) remains amongst the most common causes 
of infectious disease related death world-wide. However, despite its clinical 
importance the existing routine microbiology tests for CAP pathogens have 
significant limitations, lacking sensitivity for identifying the causative pathogen and 
only altering management in a minority of patients. For example, blood cultures 
identify a pathogen in 10% or less of CAP cases [1,2] and results are usually only 
available after 24 hours. Clinicians are therefore still required to prescribe broad-
spectrum antibiotics for the first 24 – 72 hours, which is the period of highest risk for 
clinical deterioration and death [3,4]. Even when bacteria are cultured this only 
occasionally leads to a change in treatment and may miss co-infection [2,5]. These 
limitations have led to suggestions that patients admitted with CAP do not require 
routine microbiological testing with management decisions based solely on clinical 
factors. However, not identifying the causative pathogens in CAP has important 
implications. From a public health perspective, not performing microbiological testing 
could result in failure to identify important changes in microbial aetiology or changes 
in anti-microbial resistance patterns. In the absence of microbiological testing all 
patients would be treated with prolonged broad-spectrum antibiotics that may not be 
required if, for example, Streptococcus pneumoniae was the causative pathogen, 
thereby unnecessarily increasing drug cost and potentially promoting development of 
antimicrobial resistance or anti-microbial related complications such as Clostridium 
difficile diarrhoea [6]. Finally, the relatively rare CAP patient infected with a drug-
resistant pathogen such as community acquired methicillin resistant Staphylococcus 
aureus or Pseudomonas aeruginosa may not be identified, increasing the chance of 
a poor outcome. 
 
In this issue of the European Respiratory Journal, Amaro et al.[7] report prospective 
data from a well characterised cohort of 917 immunocompetent patients on the 
characteristics of blood culture positive versus negative in CAP patients infected with 
S. pneumoniae, the most frequently isolated pathogen in this disease and which is 
frequently associated with septicaemia [8]. Indeed, Amaro et al.[7] found that 362 
(39%) of patients with pneumococcal CAP had positive blood cultures, a higher rate 
of positive culture than reported in other studies [8]. If bacteraemia is associated with 
increased risk of septic shock and mortality in hospitalised cases of S. pneumoniae 
CAP, then early detection by blood cultures would be clinically important. 
Furthermore prediction of patients at risk of bacteraemic disease before culture 
results are available would also be clinically useful, potentially leading to increased 
monitoring (e.g. high dependency care) and use of adjuvant therapy [9,10]. This 
study by Amaro et al.[7] is one of the largest sets of prospectively collected data 
available on the clinical characteristics associated with blood culture positive 
pneumococcal CAP, and provides new data on the clinical value of routine blood 
cultures for patients admitted to hospital with CAP. 
 
Amaro et al.[7] make some interesting observations. Negative blood cultures were 
more likely in patients over 65 years of age, those suffering from chronic respiratory 
disease, the use of inhaled corticosteroids and in nursing home residents. Older age 
and chronic lung disease are both associated with a substantially increased risk of S. 
pneumoniae CAP, so the negative correlation with positive blood cultures for these 
groups is a slightly unanticipated. There are several potential explanations for this 
observation; a higher proportion of these individuals could be treated with antibiotics 
before admission; due to vaccine recommendations these patients may be more 
likely to have received the pneumococcal vaccine that protects against septicaemia 
(but not pneumonia) caused by vaccine-serotypes [11]; and furthermore, due to their 
underlying lower physical reserve against illness these patients may be more likely to 
be admitted due to a milder episode of CAP than younger patients without 
comorbidities. Another interesting observation is that direct comparison of the clinical 
features of the pneumococcal CAP patients with positive blood cultures to those with 
negative blood cultures reveals relatively small differences. Although patients with 
positive blood cultures were more ill, with higher respiratory and heart rates, lower 
oxygen saturations, and higher C-reactive protein (CRP) and creatinine levels the 
absolute differences to blood culture negative patients were small and not likely to 
have major biological significance. As pneumonia complicated by septicaemia is 
generally considered a more serious infectious disease than pneumonia alone these 
data are surprising, and perhaps indicate that for S. pneumoniae the additional 
negative effects of septicaemia over pneumonia is more limited than previously 
thought. 
 
Following multivariate regression analysis the presence of pleural effusion, multi-
lobar involvement on chest radiograph and a CRP > 20 mg/dl were independently 
associated with a positive blood culture and were incorporated into a predictive 
model. When all three parameters were present, the model had an area under the 
receiver operating characteristic curve of 0.69 (95% CI 0.63-0.75) to predict a 
positive blood culture for patients with pneumococcal CAP, suggesting sufficient but 
not good discriminatory ability of the model. Of the included variables, CRP>20 mg/dl 
had the highest sensitivity, whilst the presence of a pleural effusion and multi-lobar 
infiltrates had increased specificity. Hence the presence of a high CRP, pleural 
effusion and multi-lobe disease is a reasonable marker for S. pneumoniae 
septicaemia in patients with known pneumococcal CAP. However this will have little 
clinical utility unless these parameters also differentiated pneumococcal septicaemia 
from all patients with CAP (not just pneumococcal CAP), or a point of care test for S. 
pneumoniae such as urinary antigen detection was used routinely. Previous studies 
are consistent with the present study, with pleural effusions and multi-lobar infiltrates 
associated with an increased proportion of positive blood cultures, and increased age 
and the presence of COPD associated with negative blood cultures [12–14]. These 
studies also identified additional factors associated with positive blood cultures 
including male gender, congestive heart failure, alcohol and drug abuse, 
hypoalbuminaemia, hyponatraemia, tachycardia, and hypotension [13,14] not 
corroborated by Amaro et al. [7]. Overall, these data do provide a strong degree of 
confidence that effusions and multi-lobe disease are positively and chronic lung 
disease and older age negatively associated with blood culture positive S. 
pneumoniae CAP. However, these clinical associations probably lack adequate 
sensitivity or specificity to be a particularly useful clinical tool for guiding different 
approaches to therapy for patients with CAP. 
 
One curious observation by Amaro et al.[7] is that a positive blood culture was not 
associated with poorer outcomes; although 30-day mortality was slightly higher in the 
positive blood culture group this was not statistically significant. This result is 
congruent with the limited differences in severity markers between blood culture 
positive and negative patients. However, previous studies found that positive blood 
cultures in pneumococcal pneumonia were associated with an increased risk of 
septic shock and mortality [12,15]. Furthermore, a secondary analysis of the 
Community Acquired Pneumonia Organization (CAPO) database demonstrated an 
increased mortality amongst blood culture positive pneumococcal pneumonia 
patients [14]. Technical differences may explain the discrepancy in the significance of 
a positive blood culture for S. pneumoniae on mortality. For example, in the Amaro et 
al.[7] study the overall mortality was relatively low, reducing the power of the study to 
identify differences in mortality between blood culture positive and negative patients. 
Furthermore, the older age and increased incidence of chronic lung disease may 
have offset any increased mortality associated with more severe disease in blood 
culture positive patients. False negative blood culture results due to pre-admission 
antibiotics or insensitive culture techniques could also potentially explain the lack of 
association of positive blood cultures with poor outcome. Conversely, the CAPO 
database study may have been confounded by HIV since blood culture positive 
patients without HIV did not have significant differences in the risk of mortality [14], 
and in the Capelastegui et al.[12] study a higher proportion of blood culture negative 
patients received dual antibiotic therapy including a macrolide which is associated 
with improved outcomes [16,17]. At present the clinical relevance of a positive blood 
culture for pneumococcal CAP remains unclear, but may not be as important as 
previously thought.  
 
The data from the studies of pneumococcal CAP clearly highlight that improved 
diagnostic techniques are required for pathogen detection including the presence of 
bacteraemia. Rapid immunochromatographic tests (ICT) such as the Binax NOW® 
antigen assay and novel novel multiplex urinary antigen tests increase identification 
of S. pneumoniae in patients with CAP [18–20]. Although not licensed for blood 
testing, Binax NOW® can also detect bacteraemia with high sensitivity and is useful 
for the assessment of negative conventional subcultures [21]. Molecular diagnostics 
such a polymerase chain reaction (PCR) do not depend on growth of the bacteria 
and therefore result in more positive results than culture and are not affected by prior 
antibiotic use [22,23]. Several genes have been targeted for the detection of S. 
pneumoniae by real-time (RT)-PCR and a test combining highly conserved genes 
(e.g. lytA, ply, psaA, cpsA, wgz) is likely to be highly specific [24,25]. When combined 
with other molecular techniques such as rnpB sequencing or conventional culture the 
diagnostic accuracy increases [26]. RT-PCR for S. pneumoniae also has prognostic 
implications since >103 S. pneumoniae DNA copies/ml was associated with 
increased risk of septic shock, need for mechanical ventilation and increased 
mortality [27]. Another molecular diagnostic test that has shown promise for the 
detection of S. pneumoniae is recombinase polymerase amplification (RPA) that 
does not require thermocycling so could be used as a point of care test [28]. As CAP 
may be caused by several other pathogens other than S. pneumoniae multiplex PCR 
assays that can simultaneous identify several bacterial and viral pathogens will be 
advantageous, and will help identify co-infections [22,29]. 
 
In summary, the study by Amaro et al.[7] on the clinical significance of a positive 
blood culture in patients presenting with pneumococcal CAP perhaps provides 
support for those who believe that it is not necessary to do microbiology tests in 
CAP. However, apart from the broader importance of microbiological testing in 
patients with CAP discussed in the opening paragraph, it is probably still premature 
to state that S. pneumoniae bacteraemia has little clinical relevance. Larger studies 
preferably using improved diagnostic techniques will be necessary to fully clarify the 
clinical implications of bacteraemia in patients presenting with S. pneumoniae CAP. 
Better microbiological tests are needed for CAP that can rapidly identify the 
causative pathogen(s), preferably combined with prognostic information, 
quantification of pathogen load, and detection of mutations associated with antibiotic 
resistance. Until these tests are routinely available and implemented in clinical 
practice,	 conventional cultures will remain an important diagnostic microbiological 
tool for patients admitted with CAP. 
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